Accuray (ARAY)
1.85
-0.07 (-3.65%)
At close: Mar 04, 2025, 3:59 PM
1.87
0.81%
After-hours: Mar 04, 2025, 06:32 PM EST
-3.65% (1D)
| Bid | 1.85 |
| Market Cap | 190.75M |
| Revenue (ttm) | 459.51M |
| Net Income (ttm) | -4.43M |
| EPS (ttm) | -0.04 |
| PE Ratio (ttm) | -46.37 |
| Forward PE | 16.14 |
| Analyst | n/a |
| Ask | 1.91 |
| Volume | 745,628 |
| Avg. Volume (20D) | 729,079 |
| Open | 1.88 |
| Previous Close | 1.92 |
| Day's Range | 1.80 - 1.91 |
| 52-Week Range | 1.40 - 2.95 |
| Beta | 1.46 |
About ARAY
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and m...
Industry Medical - Specialties
Sector Healthcare
IPO Date Feb 8, 2007
Employees 987
Stock Exchange NASDAQ
Ticker Symbol ARAY
Website https://www.accuray.com
Next Earnings Release
Accuray is scheduled to release its earnings on Apr 30, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+8.03%
Accuray shares are trading higher after the compan...
Unlock content with
Pro Subscription
6 months ago
+51.75%
Accuray shares are trading higher after the company reported better-than-expected Q4 sales results.
1 month ago · seekingalpha.com
Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'Impressive revenue growth remains elusive for Accuray despite the potential in China, and there are ongoing challenges with profitability, competition, and market scale. The last quarter's results sho...
